Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination

Cancer patients (CPs) have been identified as particularly vulnerable to SARS-CoV-2 infection, and therefore are a priority group for receiving COVID-19 vaccination. From the patients with advanced solid tumors, about 20% respond very efficiently to immunotherapy with anti-PD1/PD-L1 antibodies and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sisteré-Oró, Marta, Wortmann, Diana D. J., Andrade, Naína, Aguilar, Andres, Mayo de las Casas, Clara, Casabal, Florencia Garcia, Torres, Susana, Bona Salinas, Eduardo, Raventos Soler, Laura, Arcas, Andrea, Esparre, Carlos, Garcia, Beatriz, Valarezo, Joselyn, Rosell, Rafael, Güerri-Fernandez, Roberto, Gonzalez-Cao, Maria, Meyerhans, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330498/
https://www.ncbi.nlm.nih.gov/pubmed/35911701
http://dx.doi.org/10.3389/fimmu.2022.908108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330498/
https://www.ncbi.nlm.nih.gov/pubmed/35911701
http://dx.doi.org/10.3389/fimmu.2022.908108

Ejemplares similares